Issue 23 of Bioanalysis volume 9 is now available, including an editorial discussing the matrix effects, a methodology on assay signaling and a White Paper on the rise of hybrid LBA/LCMS immunogenicity assays.
In this conference report we discuss our highlights from the 10th Open Meeting of the European Bioanalytical Forum – a New Journey begins (Barcelona, Spain; 14–17 November).
Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol
This article looks at a new electrochemiluminescence immunoassay developed to measure certolizumab pegol levels in human plasma. Learn more in this article from Bioanalysis.
Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons
This review compares and discusses all available approaches that can be used to assess key assay parameters for pharmacokinetic and biomarker ligand-binding assays. Find out more in this article from Bioanalysis.
Challenges of single and multiplex biomarker validation on ‘planet Earth’ versus ‘planet Biomarkertopia’
Available to view on demand.
This presentation focuses on the current status and industry standards for Fit-for-Purpose biomarker assay validations.
A DNA methylation biomarker (POU4F3) and quantitative assay may provide a two-pronged approach to improve the preclinical identification and diagnosis of cervical cancers.
This article describes the nature of the immune response to protein therapeutics, their clinical relevance, methodology for measuring it and approaches to interpreting the data.
In this series we will be discovering what immunogenicity is, why it is important and how is it regulated and standardized.
The journal, the Society for Laboratory Automation and Screening Technology, presents a special issue highlighting the development of research assays.
In this interview, we talk to Omnia Ismaiel on her latest article, ‘Do we have mature LC–MS/MS methodology for therapeutic monoclonal antibody bioanalysis?’.